Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2011

Filing Date
Filed February 9, 2012
Period End
December 31, 2011
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed February 9, 2012. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. (NBIX) reported net income of $37.6 milliona, or $0.67 per diluted share, for 2011, compared with a net loss of $8.0 million in 2010.

Total revenues were $77.4 millionb in 2011, up from $33.5 million in 2010, driven primarily by $30.0 million in milestone revenue under the Abbott collaboration and $34.0 million of amortization of up-front license fees. The company stated it did not generate positive cash flow from operations in 2011 (net cash used in operating activities was $0.7 million) and expects a net loss in 2012 because it does not anticipate milestone revenue that year. It also expects revenue to decrease significantly in 2012.

The company is a clinical-stage developer with no approved products and an accumulated deficit of $724.7 millionc at December 31, 2011. Its lead program, elagolix for endometriosis, is partnered with Abbott International Luxembourg S.à r.l.; Abbott made a $75 million upfront payment and may pay up to $480 million in development and regulatory milestones plus up to $50 million in commercial milestones. The company expects elagolix to enter Phase III endometriosis trials in the first half of 2012, subject to finalizing a Special Protocol Assessment.

Its VMAT2 inhibitor NBI-98854 is in Phase II for tardive dyskinesia, and the indiplon insomnia NDA remains approvable, with a 2007 FDA letter setting new requirements and the company having ceased U.S. development activities. Liquidity stood at $129.1 milliond in cash, cash equivalents and investments at December 31, 2011.

In January 2012 the company completed a public offering of 10.9 million shares at $8.10 per share, with net proceeds of approximately $82.8 million. The company states its existing resources, together with investment income and future alliance payments, are sufficient for at least the next 12 months, and it has an effective shelf registration with approximately $37 million still available as of January 31, 2012.

Key Highlights

  1. Net income of $37.6 million ($0.67 diluted EPS) in 2011, versus a net loss of $8.0 million in 2010, driven by $30.0 million in Abbott milestone revenue.
  2. Total revenues rose to $77.4 million in 2011 from $33.5 million in 2010; amortization of up-front license fees increased to $34.0 million from $19.6 million.
  3. Management expects revenue to decrease significantly in 2012 and a net loss in 2012, as no milestone revenue is anticipated that year.
  4. Lead program elagolix (endometriosis, uterine fibroids) partnered with Abbott; Phase III endometriosis trials expected to start in the first half of 2012, subject to finalizing an SPA.
  5. Accumulated deficit of $724.7 million at December 31, 2011; company has not generated product revenue and does not expect sustained cash flow profitability.
  6. Cash, cash equivalents and investments of $129.1 million at December 31, 2011, plus net proceeds of approximately $82.8 million from a January 2012 offering of 10.9 million shares at $8.10.
  7. Indiplon remains an FDA-approvable product candidate subject to new requirements from the 2007 letter; the company ceased U.S. development and pre-commercialization activities.

Financial Statements

FY2011 against FY2010

Line itemFY2011FY2010Change
Revenue$77.41M$33.50M+131.1%
R&D Expenses$30.95M$31.15M−0.6%
Operating Expenses$43.49M$47.22M−7.9%
Operating Income$33.92M-$13.72M+347.2%
Net Income$37.57M-$7.97M+571.5%
EPS (Basic)$0.68$-0.15+553.3%
EPS (Diluted)$0.67$-0.15+546.7%
Shares Outstanding (Basic)55.18M52.82M+4.5%
Shares Outstanding (Diluted)56.35M52.82M+6.7%

Frequently Asked Questions

  1. Why did Neurocrine turn a profit in 2011 and will it continue?

    The 2011 profit was primarily due to $30.0 million in milestone revenue under the Abbott collaboration ($10.0 million for advancing elagolix into Phase II uterine fibroid trials and $20.0 million for the outcome of a pre-Phase III FDA meeting for endometriosis). The company expects revenue to decrease significantly in 2012 because it does not anticipate any milestone revenue that year, and it expects a net loss in 2012.

  2. What is the status of the lead drug candidate, elagolix?

    Elagolix is an oral GnRH antagonist for endometriosis and uterine fibroids, partnered with Abbott. Abbott is pursuing a Special Protocol Assessment with the FDA for the Phase III endometriosis program, and the company expects Phase III trials to begin in the first half of 2012, subject to finalizing the SPA. A Phase II uterine fibroid study of 300 women, led by Abbott, is expected to complete in late 2012.

  3. How much cash does the company have and is it funded?

    Cash, cash equivalents and investments totaled $129.1 million at December 31, 2011. The company received net proceeds of approximately $82.8 million from a January 2012 public offering. It states that existing capital resources, investment income and future alliance payments will be sufficient for at least the next 12 months, though it notes additional financing may be needed for its broader programs.

  4. What are the main risks to the investment case?

    The filing highlights that clinical trials may fail to demonstrate safety and efficacy, and that a Phase II depression trial of CRF1 antagonist 561679 showed no benefit over placebo. The company has no approved products, an accumulated deficit of $724.7 million, and depends heavily on collaborators such as Abbott. It also discloses potential dilution from its Kingsbridge CEFF facility and the uncertain future of the indiplon program after the 2007 FDA approvable letter.